Bio medicine becomes a new star of cross strait industrial cooperation

Biomedical industry is becoming a new highlight of cross strait industrial cooperation After ten years of potential and lessons, Taiwan has finally stepped out of the R & D dilemma, and the opportunity for mass production is increasingly mature However, after decades of rapid economic growth and enhanced public health awareness in the mainland, biomedicine has become one of the most competitive industries One has technological advantages and the other has market capacity Biomedicine ushers in the best opportunity for cross-strait cooperation According to the data, China is the third largest pharmaceutical market in the world and the most important export market for Taiwan's biotechnology industry Eight of Taiwan's top ten pharmaceutical companies have entered the mainland in various forms In addition, Nanguang pharmaceutical company has obtained 6 drug certificates for sale to the mainland Kanglian company cooperates with the mainland in the research and development of colorectal cancer injection products, and Jianya company cooperates with the mainland stone Pharmaceutical Group in the research and development of drugs However, compared with the scale of the mainland market, the market share of Taiwan's biotechnology export to the mainland is still very low Therefore, the mainland is the emerging market that Taiwan's biotechnology industry is most interested in The establishment of R & D center and marketing center in Taiwan is becoming the consensus of Taiwan's biotechnology industry.